Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N9PC | ISIN: CNE100003FF7 | Ticker-Symbol: 8SJ
Frankfurt
05.09.25 | 09:15
3,660 Euro
+10,91 % +0,360
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
SHANGHAI JUNSHI BIOSCIENCES CO LTD Chart 1 Jahr
5-Tage-Chart
SHANGHAI JUNSHI BIOSCIENCES CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
3,7004,02009:58

Aktueller Chart SHANGHAI JUNSHI BIOSCIENCES Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
SHANGHAI JUNSHI BIOSCIENCES CO LTD-Investoren interessieren sich auch für diese Wertpapiere
ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted...
► Artikel lesen
ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of...
► Artikel lesen
ADMA Biologics, Inc.: ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement ProcessApproval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process...
► Artikel lesen
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted...
► Artikel lesen
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of...
► Artikel lesen
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of...
► Artikel lesen
Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution- ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387...
► Artikel lesen
Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis- KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast...
► Artikel lesen
Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution- ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387...
► Artikel lesen